Evercore ISI Group maintains NovoCure at Outperform, lowers price target to $20 from $23

What happened

Evercore ISI Group kept its Outperform rating on NovoCure but lowered its price target to $20 from $23, a 13.0% decrease. The new target implies 52.6% upside from the October 29 closing price of $13.11.

Confirmed

Global impact / market context

An Outperform rating means the analyst expects the stock to beat the market, so keeping it signals continued confidence. Still, the lower target suggests the analyst expects less upside than before, which can temper how investors size their positions.

Analyst inference

The $20 target sits well above the $13.11 close, showing the analyst still sees large potential gains even after the cut. The gap between price and target reflects disagreement about how quickly NovoCure's business will grow.

Analyst inference

What to watch

1. Evercore's price target now stands at $20, down from $23, and it implies 52.6% upside from the October 29 close of $13.11, so the size of that gap is a concrete number to track. Confirmed
2. Watch whether other analysts follow Evercore by cutting their own price targets for NovoCure, which would suggest a broader shift in expectations rather than one firm's view. Proposed
3. Because the rating stayed Outperform while the target fell, track whether future analyst notes explain the cut through slower revenue growth or higher expected costs, since that reason would shape investor positioning. Analyst inference

Evidence

• Original source link unavailable